Hepatitis C illustration as blue cells. Credit: Shutterstock

Monitoring hepatitis C treatment uptake in Australia Issue 11, July 2021

This report summarises data on the prescription and distribution of hepatitis C treatments and provides insight into the initial phase of the roll-out of DAA therapy in Australia. 

Key findings
  • A total of 93,130 individuals have initiated direct acting antiviral (DAA) treatment for chronic hepatitis C virus (HCV) infection in Australia, including 88,790 individuals through Pharmaceutical Benefits Scheme (PBS) during 2016 to 2020, and an estimated 4,340 individuals through early DAA access avenues in 2014-15.
  • It is estimated 49% of the people living with chronic HCV infection in Australia in 2015 have initiated DAA treatment (27-56% across jurisdictions).
  • Among individuals initiating DAA treatment during 2016 to 2018 (n=88,790), 68% were men, and median age was 48 years (quartiles 1-3: 39-57).
Monitoring hepatitis C treatment uptake in Australia Issue 11, July 2021 392.9 KB pdf
Report contact
Year published
2021
Report type
Research reports
Research program
Viral Hepatitis Clinical Research Program
Focus areas
Viral hepatitis
Research strengths
Epidemiology and surveillance
Latest news